Clinical Trial

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 28, 2024 (before its estimated August 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
Camrelizumab is an antibody targeting programmed death receptor 1 (PD-1) and its ligand programmed death-ligand 1 (PD- L1) that is designed to boost the immune system. It does this by allowing immune cells to fight the cancer. Stereotactic body radiotherapy is a potential immunostimulatory therapy that may amplify antitumor response when combined with camrelizumab.
Protocol Amendment History 1 change
minor Trial status changed: Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT04830267
Lead Sponsor Chongqing University Cancer Hospital
Conditions Nasopharyngeal Carcinoma
Enrollment 39 participants
Start Date 2021-03-01
Primary Completion 2024-08-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2024-03-28